Enzo Biochem Gross Profit 2010-2023 | ENZ
Enzo Biochem gross profit from 2010 to 2023. Gross profit can be defined as the profit a company makes after deducting the variable costs directly associated with making and selling its products or providing its services.
Enzo Biochem Annual Gross Profit
(Millions of US $) |
| 2022 |
$42 |
| 2021 |
$54 |
| 2020 |
$24 |
| 2019 |
$23 |
| 2018 |
$41 |
| 2017 |
$46 |
| 2016 |
$46 |
| 2015 |
$43 |
| 2014 |
$42 |
| 2013 |
$39 |
| 2012 |
$47 |
| 2011 |
$48 |
| 2010 |
$45 |
| 2009 |
$37 |
Enzo Biochem Quarterly Gross Profit
(Millions of US $) |
| 2023-01-31 |
$1 |
| 2022-10-31 |
$4 |
| 2022-07-31 |
$4 |
| 2022-04-30 |
$10 |
| 2022-01-31 |
$16 |
| 2021-10-31 |
$11 |
| 2021-07-31 |
$10 |
| 2021-04-30 |
$16 |
| 2021-01-31 |
$16 |
| 2020-10-31 |
$12 |
| 2020-07-31 |
$8 |
| 2020-04-30 |
$4 |
| 2020-01-31 |
$6 |
| 2019-10-31 |
$6 |
| 2019-07-31 |
$6 |
| 2019-04-30 |
$5 |
| 2019-01-31 |
$5 |
| 2018-10-31 |
$7 |
| 2018-07-31 |
$8 |
| 2018-04-30 |
$11 |
| 2018-01-31 |
$11 |
| 2017-10-31 |
$11 |
| 2017-07-31 |
$10 |
| 2017-04-30 |
$12 |
| 2017-01-31 |
$12 |
| 2016-10-31 |
$12 |
| 2016-07-31 |
$12 |
| 2016-04-30 |
$11 |
| 2016-01-31 |
$11 |
| 2015-10-31 |
$11 |
| 2015-07-31 |
$11 |
| 2015-04-30 |
$10 |
| 2015-01-31 |
$10 |
| 2014-10-31 |
$11 |
| 2014-07-31 |
$11 |
| 2014-04-30 |
$10 |
| 2014-01-31 |
$10 |
| 2013-10-31 |
$11 |
| 2013-07-31 |
$9 |
| 2013-04-30 |
$9 |
| 2013-01-31 |
$9 |
| 2012-10-31 |
$12 |
| 2012-07-31 |
$12 |
| 2012-04-30 |
$12 |
| 2012-01-31 |
$12 |
| 2011-10-31 |
$12 |
| 2011-07-31 |
$12 |
| 2011-04-30 |
$12 |
| 2011-01-31 |
$10 |
| 2010-10-31 |
$13 |
| 2010-07-31 |
$10 |
| 2010-04-30 |
$11 |
| 2010-01-31 |
$11 |
| 2009-10-31 |
$13 |
| 2009-07-31 |
$11 |
| 2009-04-30 |
$10 |
| 2009-01-31 |
$8 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$0.106B |
$0.107B |
|
Enzo Biochem, Inc. develops, manufactures and markets health care products based on molecular biology and genetic engineering techniques, and also provides diagnostic services to the medical community. The business activities of the company are performed by one of the company's three wholly-owned subsidiaries--Enzo Diagnostics, Inc., Enzo Therapeutics, Inc., and Enzo Clinical Labs, Inc. The primary focus of the company's research is the development of products based on two technology platforms -- genetic modulation and immune modulation.
|
